cetuximab (erbitux) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Eli Lilly and Co. and outside those countries by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$226.0465 - $1130.2168

United States

$450.0500 - $1219.0400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

c225 | c-225 | centuximab | cetuximab | cétuximab | cetuximab (genetical recombination) | cetuximabum | cetxuimab | erbitux | imc-225 | imc-c225 | immunoglobulin g 1 (human-mouse monoclonal c 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal c 225 kappa - chain, dimer

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue